Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

TLThomas LeblancABAlana BlockCYChristopher Young

Discussion

Loading...

Member takes

Overview

Observational analysis reveals transfusion dependence and outcomes in older patients with AML treated with gilteritinib, suggesting implications for healthcare utilization.

Key Points

  • Many older patients with acute myeloid leukemia experienced transfusion independence after treatment with gilteritinib, improving clinical outcomes.
  • Among 962 eligible Medicare patients, 74.8% maintained red blood cell independence during the first 8 weeks post-treatment.
  • This retrospective cohort study assessed Medicare beneficiaries, providing vital insights into transfusion burden and comorbidities in AML.
  • These findings underline the potential to reduce healthcare utilization and improve quality of life among older adults receiving gilteritinib.

Cite This Study

Leblanc et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e39ehttps://doi.org/10.1182/blood-2025-1664
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  2. 2Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  3. 3Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience2025 · 6 citations
  4. 4Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  5. 5A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study2025